BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 23714484)

  • 1. The rationale and evidence for radiotherapy in the management of gastroesophageal junction tumors.
    Haustermans K
    Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV.
    Lorenzen S; Biederstädt A; Ronellenfitsch U; Reißfelder C; Mönig S; Wenz F; Pauligk C; Walker M; Al-Batran SE; Haller B; Hofheinz RD
    BMC Cancer; 2020 Sep; 20(1):886. PubMed ID: 32933498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unanswered questions in the management of gastroesophageal junction adenocarcinoma: an overview from the medical oncologist's perspective.
    Shah MA
    Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival outcomes in patients with gastric and gastroesophageal junction adenocarcinomas treated with perioperative chemotherapy with or without preoperative radiotherapy.
    Tian S; Jiang R; Madden NA; Ferris MJ; Buchwald ZS; Xu KM; Cardona K; Maithel SK; McDonald MW; Lin JY; Curran WJ; El-Rayes BF; Behera M; Patel PR
    Cancer; 2020 Jan; 126(1):37-45. PubMed ID: 31532544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study protocol of a randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma: PREACT.
    Liu X; Jin J; Cai H; Huang H; Zhao G; Zhou Y; Wu J; Du C; Long Z; Fang Y; Ma M; Li G; Zhou M; Yin J; Zhu X; Zhu J; Sheng W; Huang D; Zhu H; Zhang Z; Lu Q; Xie L; Zhang Z; Wang Y
    BMC Cancer; 2019 Jun; 19(1):606. PubMed ID: 31221115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative versus postoperative radiotherapy for locally advanced gastroesophageal junction and proximal gastric cancers: a comparison of normal tissue radiation doses.
    Tillman GF; Pawlicki T; Koong AC; Goodman KA
    Dis Esophagus; 2008; 21(5):437-44. PubMed ID: 19125798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Technical considerations in radiation therapy for gastroesophageal junction cancer.
    Pepek JM; Willett CG; Czito BG
    Semin Radiat Oncol; 2013 Jan; 23(1):51-9. PubMed ID: 23207047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus.
    Ronellenfitsch U; Schwarzbach M; Hofheinz R; Kienle P; Kieser M; Slanger TE; Jensen K;
    Cochrane Database Syst Rev; 2013 May; (5):CD008107. PubMed ID: 23728671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neo-adjuvant radiation therapy provides a survival advantage in T3-T4 nodal positive gastric and gastroesophageal junction adenocarcinoma: a SEER database analysis.
    Zhou YJ; Lu XF; Meng JL; Wang XY; Zhang QW; Chen JN; Wang QW; Yan FR; Li XB
    BMC Cancer; 2021 Jul; 21(1):771. PubMed ID: 34217249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapy in gastric cancer. From an oncological perspective].
    Wilke H; Stahl M
    Chirurg; 2009 Nov; 80(11):1023-7. PubMed ID: 19902288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junction.
    Moehler M; Gockel I; Roessler HP; Arnold D; Trarbach T; Thomaidis T; Klautke G; Rödel C; Brenner B; Lang H; Galle PR; Schimanski CC; Schmidberger H
    BMC Cancer; 2013 Feb; 13():75. PubMed ID: 23394629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer of the gastroesophageal junction: combined modality therapy.
    Ilson DH
    Surg Oncol Clin N Am; 2006 Oct; 15(4):803-24. PubMed ID: 17030275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controversies and Consensus in Preoperative Therapy of Esophageal and Gastroesophageal Junction Cancers.
    Ku GY
    Surg Oncol Clin N Am; 2017 Apr; 26(2):241-256. PubMed ID: 28279467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histopathologic Features are more Important Prognostic Factors than Primary Tumour Location in Gastro-oesophageal Adenocarcinoma Treated with Preoperative Chemoradiation and Surgery.
    Vošmik M; Laco J; Sirák I; Dvořák J; Lochman P; Hodek M; Malá P; Rejchrt S; Repák R; Leško M; Ferko A; Ryška A; Melichar B; Petera J
    Pathol Oncol Res; 2018 Apr; 24(2):373-383. PubMed ID: 28550507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative Chemoradiation Versus Chemotherapy in Gastroesophageal Junction Adenocarcinoma.
    Zafar SN; Blum M; Chiang YJ; Ajani JA; Estrella JS; Das P; Minsky BD; Hofstetter WL; Mansfield P; Badgwell BD; Ikoma N
    Ann Thorac Surg; 2020 Aug; 110(2):398-405. PubMed ID: 32289300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proposal of a Nomogram for Predicting Survival in Patients with Siewert Type II Adenocarcinoma of the Esophagogastric Junction After Preoperative Radiation.
    Liu F; Zhou R; Jiang F; Liu G; Li K; Zhu G
    Ann Surg Oncol; 2019 May; 26(5):1292-1300. PubMed ID: 30805805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preoperative and adjuvant therapies for upper gastrointestinal cancers.
    Varadhachary G; Ajani JA
    Expert Rev Anticancer Ther; 2005 Aug; 5(4):719-25. PubMed ID: 16111471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Locally advanced gastroesophageal junction tumor: a treatment dilemma.
    Ashraf N; Hoffe S; Kim R
    Oncologist; 2015 Feb; 20(2):134-42. PubMed ID: 25561508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors.
    Schulz C; Kullmann F; Kunzmann V; Fuchs M; Geissler M; Vehling-Kaiser U; Stauder H; Wein A; Al-Batran SE; Kubin T; Schäfer C; Stintzing S; Giessen C; Modest DP; Ridwelski K; Heinemann V
    Int J Cancer; 2015 Aug; 137(3):678-85. PubMed ID: 25530271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Controversies in the treatment of local and locally advanced gastric and esophageal cancers.
    Cohen DJ; Leichman L
    J Clin Oncol; 2015 Jun; 33(16):1754-9. PubMed ID: 25918302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.